World Cancer-treating Drugs Market Forecast 2017-2027

LONDON, September 20, 2017 /PRNewswire/ --

Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs

The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 101 figures - all unavailable elsewhere.

The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• World cancer-treating drugs market forecasts  from 2017-2027

• This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments:
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Hormone Therapy

Each sector is analysed and revenue forecasts presented.

• This report discusses and forecasts revenues of the top 25 anti-cancer drugs:
- Avastin
- Herceptin
- Rituxan
- Gleevec
- Revlimid
- Alimta
- Velcade
- Erbitux
- Gardasil
- Zytiga
- Xeloda
- Tarceva
- Afinitor
- Sprycel
- Tasigna
- Sutent
- Nexavar
- Xgeva
- Zoladex
- Yervoy
- Vidaza
- Treanda
- Temodar
- Faslodex
- Abraxane
- Others

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
- North America: US, Canada, Mexico
- South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America
- Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
- Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
- Rest of World: Middle East, Africa, Other Countries

• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market

• Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market:
- AstraZeneca
- Merck & Co., Inc. (Merck)
- Novartis
- Amgen
- Bristol-Myers Squibb (BMS)
- GlaxoSmithKline (GSK)
- Johnson & Johnson (J&J)
- Roche
- Eli Lilly
- Celgene

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain's study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.

Buy our report today World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1995/World-Cancer-Treating-Drugs-Market-Forecast-2017-2027

List of Companies Mentioned in the Report 

AbbVie

Active Biotech

Advaxis

Alchemia

Allergan

Amgen

AmpImmune

Argos Therapeutics

ArQule

AstraZeneca

Barvarian Nordic

Bayer

Biothera

BioXpress Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Celator Pharmaceuticals

Celgene

Cephalon

Clovis Oncology

Cyclacel

Daiichi Sankyo

Dendreon

Dr. Reddy's Laboratories

Eisai

Eli Lilly

EMA

Sanofi

EMD Serono

Galena Biopharma

Gilead

GSK

Heat Biologics

Immatics Biotechnologies

Infinity Pharmaceuticals

Inovio Pharmaceuticals

Janssen

Jennerex Biotherapeutics

Jiangsu Hengrui Medicine

Johnson & Johnson

MedImmune

Merck & Co.

Merck KGaA

Merck Sharpe and Dohme

Merrimack

Newlink

Novartis

OncoGenex

Onyx

Orion

OSi Pharmaceuticals

Petrov Institute of Oncology

Pfizer

Pharmacyclics

Progen Pharmaceuticals

Puma Biotechnology

Roche

Spectrum Pharmaceuticals

Spirogen

Sun Pharma

Sunesis Pharmaceuticals

Syndax

Takeda

Telomedix

TESARO

Teva Pharmaceuticals

Tracon Pharma

Transgene

United Therapeutics

Vaccinogen

Viventia Biotech

Xbiotech

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com